Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleBedard C, Pageau A, Fijarczyk A, et al., 2025,
FungAMR: a comprehensive database for investigating fungal mutations associated with antimicrobial resistance
, NATURE MICROBIOLOGY, Vol: 10, ISSN: 2058-5276- Cite
- Citations: 2
-
Journal articleGeorge NA, Pan D, Silva L, et al., 2025,
The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patients
, ECLINICALMEDICINE, Vol: 87 -
Journal articleBeregi S, Parag KV, 2025,
Optimal algorithms for controlling infectious diseases in real time using noisy infection data
, PLOS COMPUTATIONAL BIOLOGY, Vol: 21, ISSN: 1553-734X -
Journal articleRECOVERY Collaborative Group, 2025,
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
, Lancet Infect Dis, Vol: 25, Pages: 1000-1010BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY trial is a randomised, controlled, open-label, adaptive platform trial testing treatments for COVID-19. In this study we report the molnupiravir and nirmatrelvir-ritonavir comparisons from the RECOVERY trial. In each comparison, participants aged 18 years and older were randomly allocated (1:1) to the relevant antiviral (5 days of molnupiravir 800 mg twice daily or 300 mg nirmatrelvir and 100 mg ritonavir twice daily) in addition to usual care, or to usual care alone. The molnupiravir comparison was conducted at 75 hospitals in the UK, two in Nepal, and two in Indonesia; the nirmatrelvir-ritonavir comparison was conducted at 32 hospitals in the UK. Participants could take part in both comparisons. The primary outcome was 28-day mortality, and secondary outcomes were time to discharge alive from hospital and progression to invasive ventilation or death. Analysis was by intention to treat. Both comparisons were stopped because of low recruitment. This study is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. FINDINGS: From Jan 24, 2022, to May 24, 2023, 923 participants were recruited to the molnupiravir comparison (445 allocated to molnupiravir and 478 to usual care), and from March 31, 2022, to May 24, 2023, 137 participants were recruited to the nirmatrelvir-ritonavir comparison (68 allocated to nirmatrelvir-ritonavir and 69 to usual care). More than three-quarters of participants were vaccinated and had antispike antibodies at randomisation, and more than two-thirds were receiving other SARS-CoV-2 antivirals. In the molnupiravir comparison, 74 (17%) participants allocated to molnupiravir and 79 (17%) allocated to usual care died w
-
Journal articleMohan V, Strepis N, Mitsakakis K, et al., 2025,
Antimicrobial resistance in<i> Campylobacter</i><i> spp.</i><i> focussing</i><i> on</i><i> C.</i><i> jejuni</i><i> and</i><i> C.</i><i> coli</i> - A Narrative Review' (vol 43, pg 372, 2025)
, JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, Vol: 44, Pages: 453-454, ISSN: 2213-7165 -
Journal articleOtabil KB, Basáñez M-G, Ameyaa E, et al., 2025,
Usability, acceptability, and cost of the SD BIOLINE Ov16 rapid diagnostic test for onchocerciasis surveillance in endemic communities in the middle belt of Ghana
, PLoS Neglected Tropical Diseases, Vol: 19, ISSN: 1935-2727BackgroundPrevious studies in the Bono Region (middle belt) of Ghana have reported persistent Onchocerca volvulus infection and associated morbidities after nearly three decades of ivermectin treatment. This study aimed to assess the usability, acceptability, and cost of the Ov16 SD BIOLINE rapid diagnostic test (Ov16 RDT) in onchocerciasis surveillance activities in the middle belt of Ghana.MethodologyA cross-sectional study was conducted in 6 endemic communities in the Tain District and Wenchi Municipality. A total of 254 individuals (54% females; median age (range)=31 (5–83) years), agreed to participate in Ov16 RDT (100%), skin-snip microscopy (37%) and nodule palpation (100%). A total of 94 individuals participated in all three diagnostic tests, and post-test interviews were conducted with them, as well as with nine technicians. A cost analysis was also performed based on testing a hypothetical cohort of 400 individuals.Principal findingsSeropositivity of IgG4 antibodies against the Ov16 O. volvulus antigen was 23.6% (60/254, 95%CI = 18.8%–29.2%); microfilarial positivity 11.7% (11/94, 95%CI = 6.7%–19.8%) and nodule positivity 5.5% (14/254, 95%CI = 3.3%–9.0%). Female sex, age over 30 years, and farming occupation were all associated with higher odds of anti-Ov16 seropositivity. Among 5–9-year-olds, anti-Ov16 seropositivity was 11.1% (3/27), microfilarial positivity 23.1% (3/13) and nodule positivity 3.7% (1/27). Most participants and technicians preferred Ov16 RDT because of being less painful and invasive, easier to use and faster. Had 400 participants been tested, the total cost per individual would be US$24 (Ov16 RDT) and US$74 (skin-snip microscopy).ConclusionsOv16 RDT is more acceptable and affordable (a third of the cost) compared to skin-snipping for surveillance activities in transmission hotspots in Ghana.
-
Journal articleRECOVERY Collaborative Group, 2025,
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
, Lancet Infect DisBACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19. METHODS: Patients admitted with COVID-19 pneumonia to 107 UK hospitals were randomly assigned (1:1) to either usual care alone or usual care plus a single 1 g infusion of sotrovimab, using web-based unstratified randomisation. Participants were eligible if they were aged at least 18 years, or aged 12-17 years if weighing at least 40kg, and had confirmed COVID-19 pneumonia with no medical history that would put them at significant risk if they participated in the trial. Participants were retrospectively categorised as having a high antigen level if baseline serum SARS-CoV-2 nucleocapsid antigen was above the median concentration (the prespecified primary efficacy population), otherwise they were categorised as having a low antigen level. The primary outcome was 28-day mortality assessed by intention to treat. Safety outcomes were assessed among all participants, regardless of antigen level. Recruitment closed on March 31, 2024, when funding ended. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). FINDINGS: From Jan 4, 2022, to March 19, 2024, 1723 patients were enrolled in the RECOVERY sotrovimab comparison. Of these, 828 (48%) were assigned to usual care plus sotrovimab and 895 (52%) were assigned to usual care only. Mean patient age was 70·7 years (SD 14·8) and 1033 (60%) were male. 720 (42%) patients were classified as having a high antigen level, 717 (42%) as having a low antigen level, and 286 (17%) had unknown antigen status. 1389 (81%) patients were vaccinated, 1179 (82%) of 1438 patients with known serostatus had anti-spike antibodies at randomisation, and 1021 (>
-
Journal articleDaniel O, Heon SP, Donnelly CA, et al., 2025,
Rapid spread of African Swine Fever across Borneo
, Animals, Vol: 15, ISSN: 2076-2615African Swine Fever (ASF) reached the island of Borneo at the end of 2020. The first mortalities were recorded in wild bearded pigs (Sus barbatus) in Sabah, north-east Borneo. The virus then began to spread across the island but due to COVID-19 lockdowns the spread was difficult to monitor on the ground. With the urgent need to track this epidemic, and in the absence of traditional monitoring, the Babi Hutan Project was launched in April 2021 to gather data on pig sightings using citizen science. Any sightings of bearded pigs were requested via the website, social media and a WhatsApp hotline. Here we bring together the data from this project and other online sources to show how the virus spread across almost the entire island within a one-year period. The speed of spread appeared to increase with time following an exponential model: we estimate an average speed of spread of 0.89 km/day after 100 days since the first observation and at 4.28 km/day after 400 days. Our key recommendations are: that existing hunting bans on bearded pigs remain in place; that urgent biosecurity measures should be put in place if outbreaks occur in areas with backyard (domestic) pigs; that surviving pigs are tested for resistance; that the disease dynamics are modelled and that the International Union for Conservation of Nature (IUCN) urgently re-evaluates the bearded pig’s status.
-
Journal articleShabayek S, Haider D, Vogel V, et al., 2025,
CRISPR typing and phage content of colonizing Group B Streptococci from healthy Egyptian women
, Frontiers in Cellular and Infection Microbiology, Vol: 15, ISSN: 2235-2988Background: Streptococcus agalactiae or Group B Streptococcus (GBS) causes serious infections in neonates with a particularly high burden of disease in Africa. Maternal vaginal colonization is the primary source of neonatal transmission. Molecular surveillance of the maternal GBS population is crucial for informing maternal vaccine development and monitoring of the global circulation of GBS clones.Methods: The current study analyzes the structure and diversity of the clustered regularly interspaced palindromic repeat (CRISPR)-associated (Cas) system and phage content in colonizing GBS isolates collected from healthy pregnant women from Ismailia, Egypt. The isolates were characterized by whole-genome sequencing within the global JUNO project.Results: CRISPR arrays and phages were detected in a vast majority of GBS isolates. A strong congruence was observed between multilocus sequence typing (MLST), CRISPR profile, and phage content. Region-specific sequence types (STs) observed only in Africa were distinguishable from other lineages.Conclusions: CRISPR typing is a promising low-cost tool for investigating the population structure of GBS clones, particularly in middle- and low-income countries.
-
Journal articleRohr CM, Park S-K, Aguiar-Martins K, et al., 2025,
TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMPZQ variants.
, bioRxivThe anthelmintic praziquantel (PZQ) has been used for decades as the clinical therapy for schistosomiasis, and remains the only available drug. As a cheap and effective drug therapy for all human disease-causing Schistosoma species, usage of PZQ underpins mass drug administration strategies aimed at eliminating schistosomiasis as a public health problem by 2030. Concern over the potential emergence of resistance to PZQ is therefore warranted, as it would constitute a major threat to this approach. In terms of molecular adaptations conferring PZQ resistance, variation in the sequence and/or expression of the drug target is an obvious mechanism and should be a priority for surveillance efforts. The target of PZQ is a transient receptor potential ion channel, TRPMPZQ, which is established as a locus that regulates schistosome sensitivity to PZQ. Here, we describe the establishment of a community resource, 'TRPtracker', which coalesces data on TRPMPZQ natural variants together with measurements of individual variant sensitivity to PZQ. A compendium of laboratory-generated mutants in TRPMPZQ is also compiled in TRPtracker to map regions within TRPMPZQ critical for PZQ sensitivity. Aggregation of data from multiple research groups into TRPtracker permits rapid community-wide exchange of data, cataloguing which TRPMPZQ variants have been functionally profiled, where geographically these variants have been found, their frequency within populations and their potential impact on PZQ sensitivity.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
Contact us
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk